Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-08-12 |
2024-06 |
-2.2 |
N/A |
N/A |
N/A |
2024-05-08 |
2024-03 |
-2.2 |
-0.6 |
1.6 |
72.73% |
2024-04-05 |
2023-12 |
-2.6 |
N/A |
N/A |
N/A |
2023-11-13 |
2023-09 |
-4.8 |
-6 |
-1.2 |
-25.00% |
2023-11-13 |
2023-09 |
-4.8 |
N/A |
N/A |
N/A |
2023-08-14 |
2023-06 |
0 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-09-25 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-01-16 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2022-11-21 |
Maxim Group |
Upgrade |
|
Buy |
2022-01-19 |
Laidlaw & Co. |
Upgrade |
|
Buy |
2022-01-10 |
Aegis Capital |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2023-09-14 |
CALLAHAN JENNIFER L. |
Officer |
45.51K |
Purchase |
2022-11-22 |
GILGALLON CRAIG S. |
General Counsel |
194.85K |
Purchase |
2022-11-21 |
GIVENS GREGG WILLIAM |
Director |
184.32K |
Purchase |
2021-12-09 |
HARGROVES THOMAS JEFFREY |
Director |
45.84K |
Purchase |
2022-05-05 |
MEDEIROS CURTIS |
Director |
0.00 |
Sale |
2022-11-22 |
MYERS LAURIE |
Chief Operating Officer |
48.26K |
Purchase |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Group Inc |
123.02K |
114.40K |
0.54% |
2023-06-29 |
Geode Capital Management, LLC |
55.67K |
51.77K |
0.25% |
2023-06-29 |
Prime Capital Investment Advisors, LLC |
48.26K |
44.88K |
0.21% |
2023-06-29 |
State Street Corporation |
44.76K |
41.63K |
0.20% |
2023-06-29 |
HighTower Advisors, LLC |
34.42K |
32.02K |
0.15% |
2023-06-29 |
Envestnet Asset Management |
31.37K |
29.17K |
0.14% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Extended Market Index Fund |
123.02K |
114.40K |
0.54% |
2023-05-30 |
Fidelity Extended Market Index Fund |
103.32K |
94.02K |
0.46% |
Split |
Date |
1 : 20 |
2023-11-30 |